menu
    • menu
    [{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Biosolution \/ Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital"},{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Kyung Hee University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Kyung Hee University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Biosolution \/ Kyung Hee University Hospital"},{"orgOrder":0,"company":"Biosolution","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosolution \/ Biosolution","highestDevelopmentStatusID":"1","companyTruncated":"Biosolution \/ Biosolution"}]

    Find Clinical Drug Pipeline Developments & Deals by Biosolution

    Menu

    Biosolution

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Costal Chondrocyte

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Clinical Trial of CartiLife® in Korea

                            Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cartilage Diseases.

                            Product Name : CartiLife

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 21, 2021

                            Lead Product(s) : Autologous Costal Chondrocyte

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Costal Chondrocyte

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Clinical Trial of CartiLife® in the United States

                            Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cartilage Diseases.

                            Product Name : CartiLife

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 09, 2021

                            Lead Product(s) : Autologous Costal Chondrocyte

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chondrocytes

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Recipient : Mundipharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mundipharma, Biosolution to market CartiLife in South Korea

                            Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : Chondrocytes

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Recipient : Mundipharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Costal Chondrocyte,Autologous Chondrocyte

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Efficacy and Safety of Treatment of Articular Cartilage Lesions With CartiLife®

                            Details : CartiLife (Autologous Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Knee Injuries.

                            Product Name : CartiLife

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 04, 2018

                            Lead Product(s) : Autologous Costal Chondrocyte,Autologous Chondrocyte

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biosolution

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Costal Chondrocyte,Autologous Chondrocyte

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Kyung Hee University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

                            Details : CartiLife (Autologous Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Knee Injuries.

                            Product Name : CartiLife

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 07, 2018

                            Lead Product(s) : Autologous Costal Chondrocyte,Autologous Chondrocyte

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Kyung Hee University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth